$BLCO News

Last published 1w ago

1w agoBLCO TSX:BLCOBausch + Lomb Announces Publication of Multinational Survey Results Highlighting the Burden of Dry Eye Symptoms and Opportunities for Improved Awareness and Patient EducationBusiness WireFive-country survey found that self-reported dry eye symptoms were more common than reported health care professional diagnosis Among respondents with self-reported dry eye, many managed their symptoms themselves,
2w agoBLCOBausch + Lomb Third Quarter 2026 Earnings Call - BAUSCH & LOMB CORPEarnings Call TranscriptsGood morning, and welcome to Bausch & Lomb's 3rd Quarter 2026 Earnings Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key follow
2w agoBLCOBausch & Lomb Corp - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1mo agoBLCO TSX:BLCO BHC TSX:BHCBausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 GuidanceBusiness WireBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company, and its parent company, Bausch Health Companies Inc. (NYSE/TSX:BHC), today announced that Bausch + Lomb Board of Directors Chairman Thomas
1mo agoBLCO TSX:BLCOBausch + Lomb Advances Novel Oral Treatment for Dry AMD Following Constructive FDA MeetingBusiness WireBL1243 (tonabersat) is being developed as a potential oral treatment for patients with earlier-stage dry AMD, where treatment options remain limited Clinical development program expected to begin in 2027 Bausch
1mo agoBLCO TSX:BLCOBausch + Lomb Will Release Third-Quarter 2026 Financial Results on Oct. 28Business WireBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its third-quarter financial results on Wednesday, Oct. 28, 2026. The
2mo agoBLCO TSX:BLCOBausch + Lomb Announces European CE Mark Approval of SeeLyra™ Femtosecond LaserBusiness WireNext-generation platform provides precision and control in laser-assisted preparation for premium cataract, LASIK flap and corneal therapeutic surgeries with live swept source OCT Compact design accommodates
2mo agoBLCO TSX:BLCOBausch + Lomb Announces New Published Research on enVista Aspire™ Real World ExperienceBusiness WireMulticenter retrospective case series published in Ophthalmology and Therapy Results demonstrate enVista Aspire and enVista Aspire toric deliver good distance and functional intermediate vision in a majority of
2mo agoBLCO TSX:BLCOMost Women Don't Recognize Dry Eye as a Symptom of Perimenopause and Menopause, New Bausch + Lomb Survey FindsBusiness WireOnly 14% of peri-, menopausal and post-menopausal women recognize dry eye as a menopause-related symptom. 78% of women were surprised to learn that dry eye is a symptom of perimenopause or menopause. Women
2mo agoBLCODual-Action Eye Drop and Ocular Surface Pain R&D Update Call - BAUSCH & LOMB CORPEarnings Call TranscriptsGood evening and welcome to Bausch & Lomb's R&D update call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. Afte
2mo agoBLCO TSX:BLCOBausch + Lomb Advancing Two First-in-Class Eye Health Therapies Based on Trial ResultsBusiness WireDual-action eye drop targeting both evaporative and inflammatory dry eye disease moving to Phase 3 Positive Phase 1b results for ocular surface pain candidate validate TRPV1 antagonist approach and strengthen
3mo agoBHC BLCOBausch Health CEO Thomas J. Appio Joins Bausch + Lomb BoardPR NewswireBausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company"), today announced that its CEO, Thomas J. Appio, has been...
3mo agoBLCO TSX:BLCOBausch + Lomb Announces Board of Directors Update, Reaffirms GuidanceBusiness WireBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its Board of Directors. At the request of Bausch Health
3mo agoBLCOBausch + Lomb Second Quarter 2026 Earnings Call - BAUSCH & LOMB CORPEarnings Call TranscriptsGood morning and welcome to Bausch & Lomb's second quarter 2026 earnings call. All participants will be in the listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key,
3mo agoTSX:BLCO BLCOBausch + Lomb Delivers Broad-Based Second-Quarter Growth, Raises Full-Year 2026 GuidanceBusiness WireRevenue of $1.394 Billion Revenue Grew 9% as Reported and 8% on a Constant Currency1 Basis Compared to the Second Quarter of 2025 GAAP Net Loss Attributable to Bausch + Lomb Corporation of $14
3mo agoBLCO TSX:BLCOBausch + Lomb Launches EyeGility™ Inserter Preloaded IOL Delivery System in the United StatesBusiness WireEyeGility is designed for the enVista® family of IOLs Offers balanced push force for smooth delivery, convenient one-handed operation Available now for enVista Aspire™; will be available for enVista Envy™ in the
4mo agoBLCO TSX:BLCOBausch + Lomb Announces Phase 2 Results for Glaucoma Neuroprotective CandidateBusiness WirePhase 2 study did not meet its primary endpoint. Company will discontinue development of eye drops for glaucoma-related vision improvement but continue pursuing a sustained-release implant for the treatment of
4mo agoBLCO TSX:BLCOBausch + Lomb Introduces Orphia™, an AI-Powered Digital Health Platform Built to Return Physicians to Patient CareBusiness WireDesigned to reduce the operational burden that stands between physicians and their patients. Initial offering focuses on pre-surgery cataract education, with additional AI capabilities for ophthalmology planned
4mo agoBLCO TSX:BLCOBausch + Lomb Will Release Second-Quarter 2026 Financial Results on July 29Business WireBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its second-quarter financial results on Wednesday, July 29, 2026. The
4mo agoBLCO TSX:BLCONew Bausch + Lomb Data Show that Addressing Dry Eye Symptoms is Associated with Improved Quality of Life, Including Lower Anxiety and Increased Self-ConfidenceBusiness WireAmong dry eye sufferers who said their stress or anxiety levels were affected, most (73%) reported improvement following treatment While some sufferers (22%) were aware that dry eye symptoms could be associated
5mo agoBLCOGoldman Sachs 47th Annual Global Healthcare Conference - BAUSCH & LOMB CORPEarnings Call TranscriptsWe'll go ahead and get started. Good afternoon, everybody. Very pleased to welcome the management team here from Dao Shin Lam. Pleased to have Brent Saunders, Chief Executive Officer, and Yehia Hashad, Chief Medical Offi
5mo agoBLCOGoldman Sachs 47th Annual Global Healthcare Conference - BAUSCH & LOMB CORPEarnings Call TranscriptsWe'll go ahead and get started. Good afternoon, everybody. Very pleased to welcome the management team here from Dao Shin Lam. Pleased to have Brent Saunders, Chief Executive Officer, and Yehia Hashad, Chief Medical Offi
5mo agoBLCO TSX:BLCOBausch + Lomb Launches Blink® Triple Care Preservative Free Lubricant Eye Drops in the United StatesBusiness WireBlink Triple Care Preservative Free eye drops are made with the same clinically proven formula as Blink Triple Care and provide up to 10 hours of dry eye symptom relief‡ Delivers clinically proven 3-in-1 extended
5mo agoBLCO TSX:BLCOBausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceBusiness WireBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Chief Medical Officer and
5mo agoBLCO TSX:BLCOBausch + Lomb Announces 2026 Annual Meeting of Shareholder ResultsBusiness WireBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2026 annual meeting
5mo agoBLCO TSX:BLCOBausch + Lomb Launches PreserVision AREDS3™ Eye Vitamins in the United StatesBusiness WirePreserVision AREDS3™ eye vitamins combine clinically proven AREDS2 nutrients recommended by the National Eye Institute (NEI) to help reduce the risk of moderate-to-advanced age-related macular degeneration (AMD)
6mo agoBLCO TSX:BLCOBausch + Lomb Launches Bi-Blade+™ Dual-Port Vitrectomy Cutter in EuropeBusiness WireIncreased cutting speed of 25,000 cuts per minute1 is designed to minimize retinal traction,2 increase vitreous flow1 and reduce infusion pressure fluctuations when used with Adaptive Fluidics.3* Bi-Blade+
6mo agoBLCO TSX:BLCOBausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual MeetingBusiness WireBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that it will deliver more than 40 scientific data presentations at
6mo agoBLCOBausch + Lomb First Quarter 2026 Earnings Call - BAUSCH & LOMB CORPEarnings Call TranscriptsGood morning and welcome to Bausch & Lomb's first quarter 2026 earnings call. All participants will be on a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key, fo
6mo agoBLCO TSX:BLCOBausch + Lomb Announces First-Quarter 2026 Results, Raises Guidance Based on Strong Performance and Positive OutlookBusiness WireRevenue of $1.244 Billion Revenue Grew 9% as Reported and 6% on a Constant Currency1 Basis Compared to the First Quarter of 2025 GAAP Net Loss Attributable to Bausch + Lomb Corporation of $71 Million Adjusted
6mo agoBLCO TSX:BLCOBausch + Lomb Announces Published Review Examining the Role of B Vitamins in Reducing Risk and Progression of Age-Related Macular DegenerationBusiness WireDrawing on more than two decades of scientific evidence, a comprehensive review synthesizes more than 20 human studies highlighting the potential role of certain B vitamins in supporting eye health to help protect
6mo agoBLCO TSX:BLCOBausch + Lomb Releases 2025 Sustainability Impact ReportBusiness WireThe Broader Perspective framework sets direction for long-term environmental and social impact Bausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to
6mo agoBLCO TSX:BLCOBausch + Lomb Reports Nearly 725,000 Pounds of Contact Lens, Lens Care and Eye Care Materials Collected and Recycled Through ONE By ONE Recycling ProgramBusiness WireBausch + Lomb's ONE by ONE Recycling program helps prevent small, often overlooked eye health materials from entering landfills and waterways Program highlights the ongoing efforts of eye care practices, patients
7mo agoBLCO TSX:BLCOBausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced UpdateBusiness WireIncreased cutting speed of 25,000 cuts per minute1 is designed to minimize retinal traction,2 increase vitreous flow,1 and reduce infusion pressure fluctuations when used with Adaptive Fluidics.3* Bi-Blade+
7mo agoBLCO TSX:BLCOBausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in EuropeBusiness WireenVista Envy is the first diffractive premium IOL from Bausch + Lomb available in Europe Offers a continuous range of vision with excellent dysphotopsia tolerance EyeGility™ delivery system contributes to
7mo agoBLCO TSX:BLCOBausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual MeetingBusiness WireBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the presentation of new scientific data and events taking place
7mo agoBLCO TSX:BLCOBausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29Business WireBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will release its first-quarter financial results on Wednesday, April 29, 2026. The
7mo agoBLCO TSX:BLCOBausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of GlaucomaBusiness WireBoth primary effectiveness endpoints were met, demonstrating statistically significant and clinically meaningful intraocular pressure reduction. ELIOS is an implant-free procedure that uses excimer laser technology
8mo agoBLCO TSX:BLCOBausch + Lomb Launches R&D "Teach-in" Webinar SeriesBusiness WireBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the first event in an R&D "Teach-in" webinar series that will
8mo agoBLCO TSX:BLCOOphthalmology and Therapy Publishes Findings Showing Lifestyle-Driven Rise in Ocular Redness and Differentiated Role of LUMIFY®Business WireGlobal review highlights increasing prevalence of noninfectious ocular redness due to digital eye strain, dry eye disease, allergies and environmental exposures LUMIFY redness reliever eye drops (brimonidine
8mo agoBLCO TSX:BLCOBausch + Lomb Announces Fourth-Quarter and Full-Year 2025 Results, Provides 2026 GuidanceBusiness WireDelivered meaningful EBITDA margin expansion and operating leverage in the fourth quarter Fourth-Quarter 2025 Financial Results Revenue of $1.405 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation
10mo agoBLCO TSX:BLCOBausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.Business WireBausch + Lomb to launch fifth annual fundraising challenge during Glaucoma Awareness Month in partnership with Glaucoma Research Foundation, with all proceeds supporting glaucoma research Bausch + Lomb will also
10mo agoBLCO TSX:BLCOBausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceBusiness WireBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders, Executive Vice President and
10mo agoBLCO TSX:BLCOBausch + Lomb Announces Two Board of Directors AppointmentsBusiness WireBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Eduardo C. Alfonso, MD, and Steven H. Collis have been appointed
11mo agoBLCO TSX:BLCOBausch + Lomb Announces Refinancing of Outstanding Term B LoansBusiness WireBausch + Lomb Corporation (NYSE/TSX:BLCO) ("Bausch + Lomb" or the "company"), a leading global eye health company dedicated to helping people see better to live better, today announced that it allocated a $2,802,125,000
11mo agoBLCO TSX:BLCOBausch + Lomb to Participate in Citi Global Healthcare ConferenceBusiness WireBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Executive Vice President and
12mo agoBLCO TSX:BLCOBausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor DayBusiness WireBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will outline the next chapter of its evolution today during an investor day event at
1y agoBLCO TSX:BLCOBausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling ProgramBusiness WireBausch + Lomb's ONE by ONE Recycling Program has collected more than 690,000 pounds (approximately 114 million units) of used contact lens, eye care and lens care materials in the U.S. The program continues to grow
1y agoBLCO TSX:BLCOBausch + Lomb to Hold Investor Day on Nov. 13Business WireBausch + Lomb Corporation (NYSE/TSX:BLCO), a leading global eye health company dedicated to helping people see better to live better, will hold an investor day on Thursday, Nov. 13, 2025, at the New York Stock
1y agoBLCO TSX:BLCOBausch + Lomb Announces Third-Quarter 2025 ResultsBusiness WireRevenue of $1.281 Billion GAAP Net Loss Attributable to Bausch + Lomb Corporation of $28 Million Adjusted EBITDA (non-GAAP)1 of $243 Million; Adjusted EBITDA Excluding Acquired IPR&D (non-GAAP)1 of $243